Another recombinant MCMV-based vaccine vector expressing only the modified CD8+ T lymphocyte epitope was tested, resulting in much slower tumor growth and increased lifespan after intratumoral administration, although the vaccine had limited success when administered systematically [96]. This evidence concerns the gene CD8A and neoplasm.